Cited by 105Acute Ischemic Stroke ManagementBlood Coagulation and Thrombosis MechanismsNeurological Disorders and Treatments

Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease–activated receptor 1

Open access
Thiyagarajan, Meenakshisundaram, Fernández, José A., Lane, Steven M., Griffin, John H., Zlokovic, Berislav V.·2008·The Journal of Neuroscience

Abstract

Activated protein C (APC) is a serine protease with anticoagulant and direct cytoprotective activities. Early postischemic APC application activates the cellular protein C pathway in brain endothelium and neurons, which is neuroprotective. Whether late APC administration after a transient ischemic attack is neuroprotective and whether APC influences brain repair is not known. Here, we determined safety and efficacy of late APC and tissue-plasminogen activator (tPA) administrations in a mouse model of transient brain ischemia. tPA given at 6 h after onset of ischemia killed all mice within 2 d, whereas APC given at 6 or 24 h after ischemia onset improved significantly functional outcome and reduced spread of the ischemic lesion. At 7 d postischemia, APC multiple dosing (0.8 mg/kg, i.p.) at 6–72 or 72–144 h enhanced comparably cerebral perfusion in the ischemic border by ∼40% as shown by in vivo lectin-FITC angiography, blocked blood–brain barrier leakage of serum proteins, and increased the number of endothelial replicating cells by 4.5- to 4.7-fold. APC multidosing at 6–72 h or 72–144 h increased proliferation of neuronal progenitor cells in the subventricular zone (SVZ) by 40–50% and migration of newly formed neuroblasts from the SVZ toward the ischemic border by approximately twofold. The effects of APC on neovascularization and neurogenesis were mediated by protease-activated receptor 1 and were independent of the reduction by APC of infarction volume. Our data show that delayed APC administration is neuroprotective and mediates brain repair (i.e., neovascularization and neurogenesis), suggesting a significant extension of the therapeutic window for APC intervention in postischemic brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.3485-08.2008

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Thiyagarajan, M., Fernández, J. A., Lane, S. M., Griffin, J. H., & Zlokovic, B. V.
Affiliations
  • University of Rochester Medicine (US)
  • Scripps Research Institute (US)
Venue
The Journal of Neuroscience
Published
2008-11-26
Volume
28
Issue
48
Pages
12788-12797
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2065489547
Cited by
105
References
57
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 6 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 5 · 2017: 9 · 2016: 10 · 2015: 7 · 2014: 10 · 2013: 8 · 2012: 8
FWCI
4.47
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HL63290, HL52246, HL081528, HL31950)
  • National Heart, Lung, and Blood Institute (HL081528, HL 31950, HL63290, R01HL063290, R01HL052246, HL-52246, R01HL081528, P01HL031950, R37HL052246)
Topics
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
activated protein C, protease-activated receptor 1, transient cerebral ischemia, neurogenesis, neovascularization, subventricular zone, neural progenitor cells, neuroprotection, tissue plasminogen activator, blood-brain barrier disruption, therapeutic window, brain repair
MeSH terms
Animals, Blood-Brain Barrier, Brain, Cell Movement, Cerebral Arteries, Brain Ischemia, Disease Models, Animal, Enzyme Activation, Male, Mice, Inbred C57BL, Nerve Regeneration, Tissue Plasminogen Activator, Protein C, Reperfusion Injury, Treatment Outcome, Mice, Knockout, Neovascularization, Physiologic, Recovery of Function, Brain Infarction, Receptor, PAR-1, Cell Proliferation, Mice, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review